Interventions for patients with prostate cancer on active surveillance: a narrative review.

BJU Int · 2025 · PMC12606547 · PMID 41051130

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

a nonsignificant trendP = 0.11not close (p > 0.1)

Decipher scores performed on prostate biopsies of the ENACT trial cohort at trial screening, and at 1 and 2 years were positively associated with pathological or therapeutic progression in the AS arm (HR 1.17, 95% CI 1.01–1.35; P = 0.04) and showed a nonsignificant trend in the enzalutamide arm (HR 1.50, 95% CI 0.91–2.48; P = 0.11) [ 61 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.